House and Senate sponsors have reintroduced the Cancer Treatment Parity Act, a bill that would require insurers to provide coverage for oral anticancer drugs on terms no less favorable than coverage for intravenous chemotherapy.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
